Literature DB >> 26815465

The Glue Grant experience: characterizing the post injury genomic response.

A G Cuenca1, R V Maier2, J Cuschieri3, E E Moore4, L L Moldawer5, R G Tompkins6.   

Abstract

Despite ongoing improvements in resuscitation, care, and outcomes, traumatic injury remains a significant health care and economic burden. The causes are multifactorial, but our approach to the clinical management of these patients remains limited by our current understanding of the pathobiology of the disease. A multicenter, multidisciplinary program known as the "Inflammation and the Host Response to Injury" Large Scale Collaborative Research Program was created by the National Institute of General Medical Sciences (NIGMS, U54 GM062119-10) in 2001 in a 10-year effort to address some of these issues. Its primary goal is to describe the human genomic response to severe trauma and burns, and to examine changes in gene expression in the context of different clinical outcomes. The Program has not only successfully implemented clinical care guidelines for managing the severe trauma patient based on the best available evidence to minimize iatrogenic variability, but it has also examined the genome-wide, immune-inflammatory response in total and isolated blood leukocyte populations. This review will address current milestones as well as future directions for the Program.

Entities:  

Keywords:  Critical care; Inflammation; Polytrauma; Protocols

Year:  2011        PMID: 26815465      PMCID: PMC6541206          DOI: 10.1007/s00068-011-0148-8

Source DB:  PubMed          Journal:  Eur J Trauma Emerg Surg        ISSN: 1863-9933            Impact factor:   3.693


  45 in total

1.  Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans.

Authors:  R S Hotchkiss; K W Tinsley; P E Swanson; R E Schmieg; J J Hui; K C Chang; D F Osborne; B D Freeman; J P Cobb; T G Buchman; I E Karl
Journal:  J Immunol       Date:  2001-06-01       Impact factor: 5.422

2.  Benchmarking outcomes in the critically injured trauma patient and the effect of implementing standard operating procedures.

Authors:  Joseph Cuschieri; Jeffrey L Johnson; Jason Sperry; Michael A West; Ernest E Moore; Joseph P Minei; Paul E Bankey; Avery B Nathens; Alex G Cuenca; Philip A Efron; Laura Hennessy; Wenzhong Xiao; Michael N Mindrinos; Grace P McDonald-Smith; Philip H Mason; Timothy R Billiar; David A Schoenfeld; H Shaw Warren; J Perren Cobb; Lyle L Moldawer; Ronald W Davis; Ronald V Maier; Ronald G Tompkins
Journal:  Ann Surg       Date:  2012-05       Impact factor: 12.969

3.  Immunotherapy for sepsis--a new approach against an ancient foe.

Authors:  Richard S Hotchkiss; Steven Opal
Journal:  N Engl J Med       Date:  2010-07-01       Impact factor: 91.245

4.  Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group.

Authors:  S M Opal; C J Fisher; J F Dhainaut; J L Vincent; R Brase; S F Lowry; J C Sadoff; G J Slotman; H Levy; R A Balk; M P Shelly; J P Pribble; J F LaBrecque; J Lookabaugh; H Donovan; H Dubin; R Baughman; J Norman; E DeMaria; K Matzel; E Abraham; M Seneff
Journal:  Crit Care Med       Date:  1997-07       Impact factor: 7.598

5.  Inflammation and the host response to injury, a Large-Scale Collaborative Project: patient-oriented research core standard operating procedures for clinical care IX. Definitions for complications of clinical care of critically injured patients.

Authors:  Heather L Evans; Joseph Cuschieri; Ernest E Moore; Michael B Shapiro; Avery B Nathens; Jeffrey L Johnson; Brian G Harbrecht; Joseph P Minei; Paul E Bankey; Ronald V Maier; Michael A West
Journal:  J Trauma       Date:  2009-08

6.  Host resistance in sepsis and trauma.

Authors:  L D MacLean; J L Meakins; K Taguchi; J P Duignan; K S Dhillon; J Gordon
Journal:  Ann Surg       Date:  1975-09       Impact factor: 12.969

7.  Effect of interferon gamma on infection-related death in patients with severe injuries. A randomized, double-blind, placebo-controlled trial.

Authors:  D J Dries; G J Jurkovich; R V Maier; T P Clemmer; S N Struve; J A Weigelt; G G Stanford; D L Herr; H R Champion; F R Lewis
Journal:  Arch Surg       Date:  1994-10

8.  Improvement in process of care and outcome after a multicenter severe sepsis educational program in Spain.

Authors:  Ricard Ferrer; Antonio Artigas; Mitchell M Levy; Jesús Blanco; Gumersindo González-Díaz; José Garnacho-Montero; Jordi Ibáñez; Eduardo Palencia; Manuel Quintana; María Victoria de la Torre-Prados
Journal:  JAMA       Date:  2008-05-21       Impact factor: 56.272

9.  The impact of compliance with 6-hour and 24-hour sepsis bundles on hospital mortality in patients with severe sepsis: a prospective observational study.

Authors:  Fang Gao; Teresa Melody; Darren F Daniels; Simon Giles; Samantha Fox
Journal:  Crit Care       Date:  2005-11-11       Impact factor: 9.097

10.  The Surviving Sepsis Campaign sepsis change bundles and clinical practice.

Authors:  R Phillip Dellinger; Jean-Louis Vincent
Journal:  Crit Care       Date:  2005-11-25       Impact factor: 9.097

View more
  9 in total

1.  The challenges and advances of polytrauma care in 2012.

Authors:  Z J Balogh; H-C Pape
Journal:  Eur J Trauma Emerg Surg       Date:  2011-12       Impact factor: 3.693

2.  Metabolomics and Precision Medicine in Trauma: The State of the Field.

Authors:  Sudha P Jayaraman; Rahul J Anand; Jonathan H DeAntonio; Martin Mangino; Michel B Aboutanos; Vigneshwar Kasirajan; Rao R Ivatury; Alex B Valadka; Olena Glushakova; Ronald L Hayes; Lorin M Bachmann; Gretchen M Brophy; Daniel Contaifer; Urszula O Warncke; Donald F Brophy; Dayanjan S Wijesinghe
Journal:  Shock       Date:  2018-07       Impact factor: 3.454

3.  Biomarker Evidence of the Persistent Inflammation, Immunosuppression and Catabolism Syndrome (PICS) in Chronic Critical Illness (CCI) After Surgical Sepsis.

Authors:  Dijoia B Darden; Scott C Brakenridge; Philip A Efron; Gabriela L Ghita; Brittany P Fenner; Lauren S Kelly; Alicia M Mohr; Lyle L Moldawer; Frederick A Moore
Journal:  Ann Surg       Date:  2021-10-01       Impact factor: 13.787

4.  Reverse Engineering the Inflammatory "Clock": From Computational Modeling to Rational Resetting.

Authors:  Yoram Vodovotz
Journal:  Drug Discov Today Dis Models       Date:  2017-04-15

5.  Single-Cell Transcriptomics Reveals Compartment-Specific Differences in Immune Responses and Contributions for Complement Factor 3 in Hemorrhagic Shock Plus Tissue Trauma.

Authors:  Guang Fu; Tianmeng Chen; Junru Wu; Ting Jiang; Da Tang; Jillian Bonaroti; Julia Conroy; Melanie J Scott; Meihong Deng; Timothy R Billiar
Journal:  Shock       Date:  2021-12-01       Impact factor: 3.454

Review 6.  The Use of Multiplexing to Identify Cytokine and Chemokine Networks in the Immune-Inflammatory Response to Trauma.

Authors:  Jillian Bonaroti; Sultan Abdelhamid; Upendra Kar; Jason Sperry; Ruben Zamora; Rami Ahmd Namas; Todd McKinley; Yoram Vodovotz; Timothy Billiar
Journal:  Antioxid Redox Signal       Date:  2021-05-19       Impact factor: 7.468

7.  Understanding Physiology in the Continuum: Integration of Information from Multiple -Omics Levels.

Authors:  Kubra Kamisoglu; Alison Acevedo; Richard R Almon; Susette Coyle; Siobhan Corbett; Debra C Dubois; Tung T Nguyen; William J Jusko; Ioannis P Androulakis
Journal:  Front Pharmacol       Date:  2017-02-27       Impact factor: 5.810

8.  A disturbed balance between blood complement protective factors (FH, ApoE) and common pathway effectors (C5a, TCC) in acute COVID-19 and during convalesce.

Authors:  Krzysztof Laudanski; Tony Okeke; Kumal Siddiq; Jihane Hajj; Mariana Restrepo; Damodar Gullipalli; Wen-Chao Song
Journal:  Sci Rep       Date:  2022-08-11       Impact factor: 4.996

9.  Validation of a Visual-Based Analytics Tool for Outcome Prediction in Polytrauma Patients (WATSON Trauma Pathway Explorer) and Comparison with the Predictive Values of TRISS.

Authors:  Cédric Niggli; Hans-Christoph Pape; Philipp Niggli; Ladislav Mica
Journal:  J Clin Med       Date:  2021-05-14       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.